Palisade Bio — Third Quarter 2026 Earnings Summary

Palisade Bio initiated its global Phase 2b ASCENTRA-UC clinical trial for PALI-2108 in ulcerative colitis, dosing the first patient on October 27, 2026, with topline results expected in the fourth quarter of 2027. The company also received FDA clearance for the Phase 2a ASCENTRA-CD trial in Crohn's disease, targeting enrollment initiation in the first quarter of 2027. For the three months ended September 30, 2026, the company reported research and development expenses of $10.6 million and a net loss of $14.6 million, resulting in $113.6 million in cash and cash equivalents.